NBIX

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. After a strong five year run, Neurocrine Biosciences stock now screens as roughly in line with the market on traditional valuation checks, which raises the question of how much of the company’s growth story is already reflected in the price. Neurocrine Biosciences has returned 89.9% over the past five years, which puts current holders in a solid position but makes new entry points more sensitive to valuation. Recent clinical progress for valbenazine in tardive dyskinesia and CRENESSITY in congenital adrenal hyperplasia can support expectations for future cash flows, while any setbacks in these programs may quickly feed into what investors are willing to pay for the stock. The company scores 3 out of 6 on broader valuation checks, which presents a mixed picture rather than a clear bargain or clear overvaluation. The issue now is whether Neurocrine Biosciences’ current valuation leaves enough room for future upside, given what the recent returns and pipeline progress already imply. Find out why Neurocrine Biosciences' 33.5% return over the last year is lagging behind its peers. P/E is a useful yardstick for Neurocrine Biosciences because the company is profitable and investors often focus on earnings for mature commercial franchises. The stock currently trades on a P/E of 26.8x, compared with about 17.6x for the broader biotechs industry and 23.6x for its peer group, so you are paying a visible premium to sector and peer averages. The model implied fair P/E for Neurocrine Biosciences is 28.0x, only slightly above the current level. This suggests the market is not stretching far beyond what would typically be expected given its profile. Despite the recent positive data and study progress for valbenazine and CRENESSITY, the P/E does not look out of line with this tailored fair multiple. Overall, Neurocrine Biosciences stock appears priced roughly in line with a reasonable P/E range, rather than clearly cheap or expensive on this metric. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives pick up where Neurocrine Biosciences' valuation puzzle leaves off by spelling out what would need to be true about future growth, margins and earnings for...

Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release and conference call / webcast is as follows: Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT / 4:00 p.m. ET Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT / 4:30 p.m. ET Domestic Dial-In Number: 800-347-6865 International Dial-In Number: 203-518-9757 Conference ID: NBIX The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month. About Neurocrine BiosciencesNeurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie) NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-fi...

Neurocrine Biosciences (NBIX) said late Monday its drug INGREZZA, used to treat tardive dyskinesia,

Biotech stock Neurocrine Biosciences is hovering below its all-time high after first-quarter earnings surged more than 2,000%.

LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee. Detailed results of the vote follow: Shareholders also approved, on a non-binding advisory vote, the compensation of the Company's named executive officers, appointment of PricewaterhouseCoopers LLP to serve as the Company's auditor until the close of the Company's 2027 Annual Meeting of Shareholders, and the authorization for the board of directors to fix the auditor's remuneration. The final vote tabulation on all matters voted on at the Annual Meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company's website at www.bauschhealth.com. About Bausch HealthBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-2026-annual-meeting-of-shareholder-results-302776740.html

Xenon Pharmaceuticals XENE reported a loss of $1.17 per share in the first quarter of 2026, matching the Zacks Consensus Estimate. The company had incurred a loss of 83 cents per share in the year-ago quarter. In the reported quarter, Xenon did not generate any revenues, entirely missing the Zacks Consensus Estimate of $15 million. Due to the lack of a marketed product, the company recognizes only periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX. In the year-ago quarter, XENE recognized $7.5 million in revenues following a milestone payment from Neurocrine Biosciences in connection with the progress of NBI-921355 into a clinical-stage study. In the first quarter, research and development (R&D) expenses increased 45% year over year to $88.5 million. The uptick was primarily due to increased expenses related to Xenon’s ongoing azetukalner late-stage studies in epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Costs incurred in supporting the early-stage studies of XEN1701 and XEN1120, as well as increased personnel-related costs, also contributed to higher R&D expenses. General and administrative expenses totaled $23.8 million in the reported quarter, up 25% year over year due to higher personnel expenses from a larger workforce and increased professional and consulting fees. Xenon had cash, cash equivalents and marketable securities worth $1,339.6 million as of March 31, 2026, compared to $586.0 million as of Dec. 31, 2025. During the reported quarter, the company raised net proceeds of $130 million through its ATM program and an additional $707.6 million via a public offering. Based on its current operating plans, Xenon expects its existing cash position to support operations into 2029. Year to date, XENE shares have gained 24.9% against the industry’s 0.2% decline. Image Source: Zacks Investment Research In March 2026, Xenon announced positive top-line data from the phase III X-TOLE2 study, which evaluated its lead pipeline candidate, azetukalner, for treating focal onset seizures (FOS). The X-TOLE2 study evaluated the efficacy, safety and tolerability of 15 mg and 25 mg doses of azetukalner, given with food as an add-on treatment in patients with FOS. The study met its primary endpoint, showing a median percent change (MPC) in monthly FOS frequency from baseline to week 12 f...

As you might know, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) just kicked off its latest quarterly results with some very strong numbers. It was overall a positive result, with revenues beating expectations by 6.4% to hit US$815m. Neurocrine Biosciences also reported a statutory profit of US$1.91, which was an impressive 61% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Taking into account the latest results, the most recent consensus for Neurocrine Biosciences from 18 analysts is for revenues of US$3.76b in 2026. If met, it would imply a huge 21% increase on its revenue over the past 12 months. Statutory earnings per share are forecast to tumble 25% to US$5.01 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.72b and earnings per share (EPS) of US$4.59 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates. View our latest analysis for Neurocrine Biosciences The consensus price target was unchanged at US$191, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Neurocrine Biosciences analyst has a price target of US$251 per share, while the most pessimistic values it at US$144. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Neurocrine Biosciences shareholders. Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Neurocrine Biosciences' growth to accelerate, with the forecast 29% a...

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026. "Neurocrine's strong first-quarter performance reflects continued momentum across our commercial portfolio, as we advance our growth strategy and diversify across therapeutic areas," said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We delivered $811 million in net product sales, representing 44% year-over-year growth, driven by continued strong demand for INGREZZA and CRENESSITY® (crinecerfont). Our recently announced agreement to acquire Soleno Therapeutics further underscores our commitment to address conditions with significant unmet need and accelerate revenue growth. With multiple first-in-class commercial medicines and the deepest pipeline in our history, Neurocrine is well-positioned to deliver transformative therapies for patients and drive sustained growth." Net Product Sales Highlights Total first-quarter 2026 net product sales were $811.0 million, representing 44% growth year-over-year. INGREZZA first-quarter 2026 net product sales were $656.9 million, representing 20% growth year-over-year. Results reflected double-digit prescription volume growth in TRx and record NRx driven by strong patient demand, partially offset by a lower net price compared to the first quarter of 2025. CRENESSITY first-quarter 2026 net product sales were $153.3 million, driven by strong patient demand with approximately 80% reimbursement for dispensed prescriptions in the first quarter 2026. Total revenues for the first quarter of 2026 were $814.5 million, compared with $572.6 million in the prior-year period, a 42% increase. Recent Clinical and Corporate Developments Entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total transaction equi...

Neurocrine Biosciences (NBIX) reported $814.5 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 42.3%. EPS of $1.94 for the same period compares to $0.08 a year ago. The reported revenue represents a surprise of +9.8% over the Zacks Consensus Estimate of $741.78 million. With the consensus EPS estimate being $1.68, the EPS surprise was +15.31%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product sales, net- INGREZZA: $656.9 million compared to the $595.65 million average estimate based on eight analysts. The reported number represents a change of +20.5% year over year. Revenues- Product sales, net: $811 million versus the eight-analyst average estimate of $720.97 million. The reported number represents a year-over-year change of +43.9%. Revenues- Product sales, net- CRENESSITY: $153.3 million compared to the $121.77 million average estimate based on eight analysts. Revenues- Collaboration revenue: $3.5 million versus the seven-analyst average estimate of $7.72 million. The reported number represents a year-over-year change of -60.7%. Revenues- Product sales, net- Other: $4.3 million versus $4.1 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change. View all Key Company Metrics for Neurocrine here>>> Shares of Neurocrine have returned +1.2% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report...

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Tuesday reported first-quarter net income of $197.9 million. On a per-share basis, the San Diego-based company said it had net income of $1.91. Earnings, adjusted for one-time gains and costs, came to $1.94 per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.68 per share. The biopharmaceutical company posted revenue of $814.5 million in the period, which also topped Street forecasts. Nine analysts surveyed by Zacks expected $741.8 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NBIX at https://www.zacks.com/ap/NBIX

Neurocrine Biosciences (NBIX) reported Q1 adjusted earnings late Tuesday of $1.94 per diluted share,

Record quarterly revenue: Neurocrine reported Q1 net product sales above $800 million, driven primarily by INGREZZA (Q1 sales $657M), and reaffirmed full-year INGREZZA guidance of $2.7–$2.8 billion. CRENESSITY momentum and data: CRENESSITY posted $153 million in Q1 with strong persistency, favorable reimbursement and ~1,200 prescribers, and two‑year Phase III data showed durable glucocorticoid dose reductions with no new safety signals. Pipeline growth and Soleno timeline: Neurocrine plans multiple Phase I/II starts in 2026 and expects 2027 readouts for several programs (osavampator, direclidine, NBIP‑2118), while the acquisition of Soleno Therapeutics (adding VYKAT XR) remains on track to close in Q2. Interested in Neurocrine Biosciences, Inc.? Here are five stocks we like better. 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) reported first-quarter 2026 results highlighted by record quarterly revenue and continued growth from its two commercial products, INGREZZA and CRENESSITY, while company executives also discussed pipeline progress and the expected closing timeline for its pending acquisition of Soleno Therapeutics. Chief Executive Officer Kyle Gano said the company’s first-quarter performance reflected “meaningful progress” toward its goal of expanding and diversifying its revenue base. For the first time in company history, quarterly net product sales exceeded $800 million, representing 44% year-over-year growth, which Gano said was “primarily driven by INGREZZA.” → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals Chief Financial Officer Matthew Abernethy said Neurocrine delivered more than $800 million in total revenue, with “over 40% year-over-year growth.” INGREZZA first-quarter sales were $657 million, up 20% year-over-year, driven by “double-digit volume growth and record new patient additions,” he said. Abernethy added that when adjusting for one less order week in the prior-year quarter, growth was approximately 11%. Neurocrine reaffirmed its full-year 2026 INGREZZA guidance of $2.7 billion to $2.8 billion. Abernethy said the company plans to revisit guidance after the first half of the year, consistent with its historical approach. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches Is Mid-Cap...